Vorinostat in combination with gemcitabine plus platinum in patients with advanced non-small-cell lung cancer: A phase I, dose-escalation study

被引:3
|
作者
Misset, J.
Tredaniel, J.
Descourt, R.
Morot-Sibilot, D.
Zalcman, G.
Gachard, E.
Garcia-Vargas, J.
Rizvi, S.
Reiser, D.
Roben, L.
机构
[1] Hop St Louis, Paris, France
[2] Inst Cancerol & Hematol, Brest, France
[3] DMAS Pneumol Oncol Thorac, Grenoble, France
[4] CHU Caen, F-14000 Caen, France
[5] MSD, Paris, France
[6] Merck Res Labs, Upper Gwynedd, PA USA
关键词
D O I
10.1200/jco.2008.26.15_suppl.14601
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
14601
引用
收藏
页数:1
相关论文
共 50 条
  • [1] PHASE I DOSE-ESCALATION STUDY OF VORINOSTAT COMBINED WITH GEMCITABINE AND PLATINUM AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER
    Descourt, R.
    Zalcman, G.
    Moro-Sibilot, D.
    Tredaniel, J.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Reiser, D.
    Roben, E.
    Rizvi, S.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 111 - 111
  • [2] Phase I dose-escalation study of vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small-cell lung cancer (NSCLC)
    Teixeira, L.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J. L.
    Gachard, E.
    Rizvi, S.
    Roben, E.
    Zalcman, G.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 554 - 554
  • [3] Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
    Tredaniel, J.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Roben, E.
    Zalcman, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study
    Reck, Martin
    Frickhofen, Norbert
    Cedres, Susana
    Gatzemeier, Ulrich
    Heigener, David
    Fuhr, Heinz-Georg
    Thall, Aron
    Lanzalone, Silvana
    Stephenson, Patricia
    Ruiz-Garcia, Ana
    Chao, Richard
    Felip, Enriqueta
    [J]. LUNG CANCER, 2010, 70 (02) : 180 - 187
  • [5] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    [J]. British Journal of Cancer, 2018, 118 : 462 - 470
  • [6] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    [J]. BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [7] A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer
    Kaira, Kyoichi
    Sunaga, Noriaki
    Yanagitani, Noriko
    Imai, Hisao
    Utsugi, Mitsuyoshi
    Shimizu, Yasuo
    Iijima, Hironobu
    Tomizawa, Yoshio
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Saito, Ryusei
    Mori, Masatomo
    [J]. ANTI-CANCER DRUGS, 2007, 18 (04) : 471 - 476
  • [8] A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer
    Decker, R. H.
    Gettinger, S. N.
    Wilson, L. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H. G.
    Lanzalone, S.
    Wang, E.
    Chao, R.
    Felip, E.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 390 - 390
  • [10] A phase I dose escalation study of sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H.
    Lanzalone, S.
    Lechuga, M. J.
    Wang, E.
    Chao, R.
    Felip, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)